Development Corp. (Acq 2017) Viela Bio Inc (Acq 2021) Products Amgen's approved drugs or therapeutic biologicals include: Aimovig (erenumab-aooe) for migraine headaches Aranesp (darbepoetin alfa) for anemia Blincyto (blinatumomab for the treatment of acute lymphoblastic leukemia) Corlanor (ivabradine) Enbrel (etanercept) for various forms of arthritis Epogen (erythropoietin) for anemia Evenity (romosozumab-aqqg) for osteoporosis Imlygic (talimogene laherparepvec) for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery Kyprolis (carfilzomib) Lumakras (sotorasib) Neulasta (pegfilgrastim) for neutropenia Neupogen (granulocyte colony-stimulating factor) for neutropenia Nplate (romiplostim) for chronic immune thrombocytopenic purpura Parsabiv (etelcalcetide) Prolia (denosumab) for postmenopausal osteoporosis Repatha (evolocumab) Sensipar/Mimpara (cinacalcet for primary and secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure) Tezspire (tezepelumab) for asthma Vectibix (panitumumab for colon cancer) Xgeva (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors) Products developed and then sold off Kepivance (palifermin for oral mucositis, sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008 StemGen (ancestim) for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells) (sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008) Kineret (anakinra) for rheumatoid arthritis, exclusively licensed to Biovitrium, now Swedish Orphan Biovitrum, in December 2008 Pipeline and clinical trials In December 2013, Amgen had 11 drugs in Phase III clinical trials. In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without. Later in the same week, the company in conjunction with AstraZeneca reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis. In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease. In June 2015, Amgen presented Phase II clinical trial data for their anti-CGRP antibody AMG 334 for migraine, approved for sale as Aimovig in 2019. In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation. In May 2021, sotorasib received accelerated approval from FDA for treatment